Respiratory

Biologics directed at type 2 inflammation appear to offer the most promising therapeutic option for patients with eosinophilic chronic obstructive pulmonary disease (COPD), according to a multicriteria decision analysis of clinical trials.

Solid-organ transplant recipients face a markedly higher risk of developing nontuberculous mycobacterial disease compared with the general population, and this risk translates into greater long-term mortality, according to findings from a large population-based cohort study.

Interferon-induced transmembrane protein 3 (IFITM3) has been identified as a critical regulator of immunotherapy response in small cell lung cancer (SCLC), with new findings showing its potential role as both a predictive biomarker and therapeutic target.

A first-in-human trial has demonstrated encouraging clinical activity and manageable safety for the DLL3-targeted antibody-drug conjugate SHR-4849 in patients with relapsed small cell lung cancer (SCLC).

Paternal prepubertal exposure to passive smoke is associated with impaired lung function trajectories in their children, persisting from childhood into middle age and raising the risk of chronic obstructive pulmonary disease (COPD).

Children with asthma face a heightened risk of fractures, particularly when treated with corticosteroids, according to findings from a large nationwide cohort study.

GLP-1 receptor agonists (GLP-1RA) are emerging as a potential therapeutic option for patients with obstructive sleep apnea (OSA), according to a recent review that examined growing clinical evidence.

Telemedicine follow-up significantly improved quality of life and inhaler use techniques among patients with advanced chronic obstructive pulmonary disease (COPD), according to a randomized controlled trial.